Grifols SA Ordinary Shares - Class A GRF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if GRF is a good fit for your portfolio.
News
-
Grifols’ Biotest to achieve USD 1 billion in US sales of Yimmugo® over next seven years
-
Grifols completes sale of a 20% equity stake in SRAAS and forges strategic alliance with Haier Group
-
Grifols’ Biotest receives FDA approval for innovative Yimmugo® immunoglobulin to treat primary immunodeficiencies
-
Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C.
-
Grifols shares rebound after KPMG greenlights accounts in wake of short-seller's report
-
Grifols' shares plunge further on short-seller's new report
-
Grifols Shares Rise on $1.76 Billion Sale of 20% Stake in Shanghai RAAS to Pay Down Debt
-
Grifols Shares Rise on Potential Sale of Shanghai RAAS Stock for $1.5 Billion
Trading Information
- Previous Close Price
- €8.42
- Day Range
- €8.25–8.68
- 52-Week Range
- €6.36–15.92
- Bid/Ask
- — / —
- Market Cap
- €5.86 Bil
- Volume/Avg
- 1.9 Mil / 2.8 Mil
Key Statistics
- Price/Earnings (Normalized)
- 36.32
- Price/Sales
- 0.89
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 23,737
- Website
- https://www.grifols.com
Competitors
Valuation
|
Metric
|
GRF
|
4502
|
CSL
|
|---|---|---|---|
Price/Earnings (Normalized) | 36.32 | 16.09 | 30.70 |
Price/Book Value | 1.01 | 0.92 | 5.70 |
Price/Sales | 0.89 | 1.57 | 6.83 |
Price/Cash Flow | 10.15 | 7.69 | 35.62 |
Price/Earnings
GRF
4502
CSL
Financial Strength
|
Metric
|
GRF
|
4502
|
CSL
|
|---|---|---|---|
Quick Ratio | 0.63 | 0.51 | 0.95 |
Current Ratio | 2.79 | 1.11 | 2.15 |
Interest Coverage | 1.31 | 1.35 | 7.21 |
Quick Ratio
GRF
4502
CSL
Profitability
|
Metric
|
GRF
|
4502
|
CSL
|
|---|---|---|---|
Return on Assets (Normalized) | 1.30% | 5.19% | 8.11% |
Return on Equity (Normalized) | 4.69% | 11.01% | 18.17% |
Return on Invested Capital (Normalized) | 3.45% | 7.28% | 10.94% |
Return on Assets
GRF
4502
CSL
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| Dvzfqysbjz | Kclp | $808.7 Bil | |||
| Johnson & Johnson
JNJ
| Yhshhyhss | Dxbl | $350.6 Bil | |||
| Merck & Co Inc
MRK
| Pdmccmqz | Fcgwv | $318.8 Bil | |||
| AbbVie Inc
ABBV
| Qnvsvnhdz | Nqlg | $289.3 Bil | |||
| AstraZeneca PLC ADR
AZN
| Tgdlnwrrg | Pcz | $236.4 Bil | |||
| Novartis AG ADR
NVS
| Gtykzdnw | Dbhdh | $220.2 Bil | |||
| Roche Holding AG ADR
RHHBY
| Gjjzctlzn | Mxc | $218.3 Bil | |||
| Amgen Inc
AMGN
| Jxrtzpwf | Rvsq | $166.0 Bil | |||
| Pfizer Inc
PFE
| Zlyckszlp | Fwfc | $157.0 Bil | |||
| Sanofi SA ADR
SNY
| Hknjrxfvw | Jcmr | $121.3 Bil |